Cover Image
市場調查報告書

參天製藥 :產品平台分析

Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 240937
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
參天製藥 :產品平台分析 Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 64 Pages
簡介

參天製藥是開發、製造醫藥品、成藥及醫療機器的日本製藥公司。該公司除了特別緻力於眼藥之外,也製造抗風濕劑,成藥等。

本報告提供參天製藥的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

參天製藥的基本資料

參天製藥概要

  • 主要資訊
  • 企業資料

參天製藥:R&D概要

  • 主要的治療範圍

參天製藥:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

參天製藥:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 申請被不受理了的/被撤消了的產品/聯合治療模式 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

參天製藥:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

參天製藥:藥物簡介

  • (tafluprost + timolol mate)
  • cyclosporine
  • diquafosol tetrasodium
  • tafluprost
  • levofloxacin
  • sirolimus
  • DE-117
  • latanoprost
  • lomerizine
  • DE-120
  • dexamethasone dipropionate
  • SA-14867
  • SA-981
  • TRC-105

參天製藥:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

參天製藥:最近的開發平台趨勢

參天製藥:暫停中的計劃

參天製藥:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • DE-098
    • DE-102
    • DE-104
    • DE-105
    • evodenoson
    • gefarnate
    • olmesartan
    • ONO-6126
    • rivoglitazone

參天製藥:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06914CDB

Summary

Global Markets Direct's, 'Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Santen Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Santen Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Santen Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Santen Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Santen Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Santen Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Santen Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Santen Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Santen Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Santen Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Santen Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Santen Pharmaceutical Co., Ltd. Snapshot
    • Santen Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Santen Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Santen Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Santen Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Santen Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Santen Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Santen Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Santen Pharmaceutical Co., Ltd. - Drug Profiles
    • (tafluprost + timolol maleate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diquafosol tetrasodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sirolimus
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tafluprost
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levofloxacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DE-117
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DE-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • latanoprost
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lomerizine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexamethasone dipropionate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SA-14867
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRC-105
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Santen Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Santen Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Santen Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Santen Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Santen Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Santen Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Santen Pharmaceutical Co., Ltd. - Dormant Projects
  • Santen Pharmaceutical Co., Ltd. - Dormant Projects
  • Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • DE-102
      • DE-104
      • DE-105
      • evodenoson
      • gefarnate
      • olmesartan
      • ONO-6126
      • rivoglitazone
  • Santen Pharmaceutical Co., Ltd. - Company Statement
  • Santen Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Santen Pharmaceutical Co., Ltd., Key Information
  • Santen Pharmaceutical Co., Ltd., Key Facts
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Santen Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Santen Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015
  • Santen Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Santen Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Santen Pharmaceutical Co., Ltd. - Pre-Registration, 2015
  • Santen Pharmaceutical Co., Ltd. - Filing rejected/Withdrawn, 2015
  • Santen Pharmaceutical Co., Ltd. - Phase III, 2015
  • Santen Pharmaceutical Co., Ltd. - Phase II, 2015
  • Santen Pharmaceutical Co., Ltd. - Phase I, 2015
  • Santen Pharmaceutical Co., Ltd. - Preclinical, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Santen Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2015
  • Santen Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015
  • Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2015
  • Santen Pharmaceutical Co., Ltd., Other Locations
  • Santen Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Santen Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Santen Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Santen Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Santen Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top